Navigation Links
Therapure Biopharma Inc. wins a 2013 CMO Leadership Award in All 5 Categories: Quality, Reliability, Innovation, Productivity and Regulatory
Date:9/11/2013

Mississauga, Ontario (PRWEB) September 11, 2013

Therapure Biopharma Inc. announced today that its biomanufacturing division, Therapure Biomanufacturing, has won the 2013 CMO Leadership Award as a leader in all five categories: Quality, Reliability, Innovation, Productivity and Regulatory.

The CMO Leadership Award is based on the responses of more than 10,000 pharmaceutical and biopharmaceutical executives in a survey conducted by Nice Insight and presented by Life Science Leader Magazine. The award recognizes contract manufacturing organizations that achieve customer perception scores in the top 20% in the five industry-driven categories.

In accepting the 2013 award, Therapure Biopharma Inc. President and Chief Executive Officer, Mr. Nick Green said, “It is an honor to be recognized for a 3rd consecutive year for the CMO Leadership Award, and once again in all five categories. This award recognizes the diligence, passion and contribution of our employees who strive to meet our clients’ needs and produce the highest quality therapeutics possible. The 5 categories are critical to our clients’ success and more importantly for patient well being.”

Theapure Biomanufacturing will be recognized as an award winner in the annual CMO Leadership Awards supplement published by Life Science Leader in October.

To meet the Therapure Contract Development and Manufacturing Organization (CDMO) team and discuss how they can help you with your biomanufacturing needs, they invite you to visit Therapure at the:

  •     BioProcess International conference, Booth 906, September 17–19th, 2013, in Boston, MA
  •     ContractPharma conference, Booth 10, September 19th, 2013, in New Brunswick, NJ.

Therapure Biopharma Inc. is also pleased to announce the launch of its new website, found at http://www.therapurebio.com. The new website, designed with a fresh new look and user-friendly navigation, reflects the unique business structure of the organization, which is comprised of Therapure Biomanufacturing (http://www.therapurebio.com/CDMO) the award-winning CDMO division, and Therapure Innovations (http://www.therapurebio.com/innovations), the proprietary drug pipeline and platform technology research and development division.

About Therapure Biomanufacturing
Therapure Biomanufacturing is a global contract development and manufacturing organization (CDMO) offering integrated services for developing, manufacturing, purifying and packaging complex biological therapeutics. Our scientific and manufacturing expertise, as well as our flexible state-of-the-art cGMP facility, provides clients with optimal biomanufacturing solutions to advance their biotherapeutics from discovery to market.

About Therapure Biopharma Inc.
Therapure Biopharma Inc. is an integrated biopharmaceutical company focused on complex biological therapeutics and technologies that can provide new options for patient care. It is comprised of Therapure Biomanufacturing, the award-winning CDMO division and Therapure Innovations, the proprietary drug pipeline and platform technology research and development division. Therapure Biopharma Inc.’s 130,000 sq. ft. cGMP facility includes biomanufacturing, research and quality-control laboratories and is built to meet FDA (USA), HPFB (Canada), EMA (Europe) and MHRA (UK) standards.

For more information, please visit http://www.therapurebio.com
Company Contact:
Dina Iezzi
Director, Marketing and Special Projects
diezzi(at)therapurebio(dot)com
905-286-6270

Read the full story at http://www.prweb.com/releases/2013/9/prweb11111116.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
3. CeNeRx BioPharma Completes $4.85 Million Financing
4. PDL BioPharma Completes Regular Quarterly Dividend Payment
5. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
6. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
7. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
8. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
9. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
10. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
11. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):